Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

pacritinib

Novartis building

Novartis’ Cosentyx cleared for wider use in Europe

Approved for psoriatic arthritis and ankylosing spondylitis

- PMLiVE

FDA accepts Sandoz filing for biosimilar Neulasta

Theversion of Amgen's blockbuster will have a 10-month review period

- PMLiVE

FDA approves Exelixis/Genentech’s melanoma combo Cotellic

Willprovide the first direct competition to Novartis' Mekinist in the US

- PMLiVE

Novartis curates interactive history of medicine exhibition

Beautiful Medicine highlights nature's role in the past and future ofdevelopment

- PMLiVE

Baxter appoints Jose Almeida chairman and CEO

Will take over from Robert Parkinson Jr in Janary

- PMLiVE

Novartis’ Cosentyx off to a flyer in psoriasis

Year-to-date sales reach $140m for recently approved drug

EU flag

CHMP October meeting gives recommendations for Pfizer and MSD

But the regulatory advisors sound note ofcaution on Biogen’s Tecfidera

- PMLiVE

Novartis’ Cosentyx on course for new European indications

CHMP recommends its approval to treat ankylosing spondylitis and psoriatic arthritis

- PMLiVE

Novartis adds to immuno-oncology pipeline once again

Aims to catch up with rivals BMS and Merck & Co.

- PMLiVE

Novartis Access Scheme launches in Kenya

Expands affordable treatment options against chronic diseases

- PMLiVE

Novartis signs $500m immuno-oncology deal

Gains access to Xoma's TGFb antibody programme

- PMLiVE

Novartis’ Cosentyx effective in psoriatic arthritis study

Further supports drugs ability to reduce progression of damage to joints

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links